Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy /

Detalles Bibliográficos
Clasificación:Libro Electrónico
Autor principal: Nagaraju, Ganji Purnachandra (Autor)
Formato: Electrónico eBook
Idioma:Inglés
Publicado: London : Academic Press, [2019]
Edición:First edition.
Colección:Cancer sensitizing agents for chemotherapy ; v. 5.
Temas:
Pancreas > Cancer.
Chemotherapy.
Drug resistance in cancer cells.
Drug Resistance, Neoplasm
Pancreatic Neoplasms > drug therapy
Drug Therapy
Pancreatic Neoplasms
Pancr�eas > Cancer.
Chimioth�erapie.
Cellules canc�ereuses > R�esistance aux m�edicaments.
HEALTH & FITNESS > Diseases > General.
MEDICAL > Clinical Medicine.
MEDICAL > Diseases.
MEDICAL > Evidence-Based Medicine.
MEDICAL > Internal Medicine.
Drug resistance in cancer cells
Chemotherapy
Pancreas > Cancer
Internet Resources.
Acceso en línea:Texto completo
Texto completo
Tabla de Contenidos:
  • Front Cover; Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy; Copyright; Dedication; Contents; Contributors; About the Editor; About the Series Editor; Aims and Scope for Series ""Cancer Sensitizing Agents for Chemotherapy; Preface; Chapter 1: Overview of Pancreatic Cancer Biology; Introduction; Pathogenesis and Molecular Biology; Three Biological Stages of Cancer Development; Initiation; Clonal Expansion; Oncogenesis; KRAS; Raf/Mitogen-Activated Protein Kinase (MAPK) Cascade; Phosphoinositide 3-Kinase/ATK Cascade; Nuclear Factor Kappa B Signaling Cascade
  • Tumor Suppressor GenesCDKN2A; TP53; SMAD4; Introduction to Local and Distant Microenvironments; Familial Pancreatic Cancers; Conclusions; References; Further Reading; Chapter 2: Chemoresistance in Pancreatic Cancer: Emphasis on Age and Gender; Introduction; Pancreatic Cancer Incidences and Prognosis: Association of Age and Gender; Chemoresistance: Association With Age and Gender; Mechanisms Associated With Chemoresistance; Factors Modulated in Various Age Groups; Conclusion; Acknowledgments; References; Chapter 3: EMT Contributes to Chemoresistance in Pancreatic Cancer; Introduction
  • Gemcitabine SensitivityGemcitabine and Chemoresistance; Role of Gemcitabine in Targeting Signaling Pathways; Conclusion; Acknowledgment; References; Chapter 5: Pancreatic Cancer and Possible Therapeutic Options; Introduction; Reasons Behind the Above Statistics?; Brief Outline of Treatment; Tumor-Node-Metastasis Staging and Clinical Classification; Modalities for Evaluating TNM Staging; Clinical Classification; Treatment Options for Pancreatic Adenocarcinoma; Localized Surgically Resectable Stage I and II Disease; Adjuvant Therapy; Gemcitabine and 5-Fluorouracil; Gemcitabine and S-1
  • Gemcitabine and CapecitabineAdjuvant Chemoradiation; Gemcitabine Plus Nab-Paclitaxel; Neoadjuvant Therapy; Adjuvant Therapy in Borderline Removable Pancreatic Carcinoma; Evidence Supporting Neoadjuvant Therapy; FOLFIRINOX as Neoadjuvant Therapy; NAC-GSL (Neoadjuvant Chemotherapy-Gemcitabine, S-1, LV); Metastatic Pancreatic Cancer: Treatment Options; Early Period; First-Line Therapies; FOLFIRINOX; PRODIGE-4/ACCORD-11 Trial; Outcomes of PRODIGE-4/ACCORD-11 Trial; Precautionary and Toxicity Reducing Strategies; Gemcitabine Plus Nab-Paclitaxel; The MPACT Trial

Ejemplares similares